JTC Inc. (KOSDAQ:950170)

Verve Therapeutics Income Statement

Financials in millions KRW. Fiscal year is March - February.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	May 31, 2025	Feb 28, 2025	Feb 29, 2024	Feb 28, 2023	Feb 28, 2022	Feb 28, 2021
Other Revenue	-0	-	-	-	-0	0
Revenue	325,846	308,621	149,993	35,810	13,969	18,171
Revenue Growth (YoY)	58.54%	105.76%	318.86%	156.35%	-23.12%	-96.75%
Cost of Revenue	89,763	85,981	35,265	8,160	22,297	21,906
Gross Profit	236,083	222,640	114,728	27,650	-8,328	-3,735
Selling, General & Admin	201,944	189,399	94,684	29,436	16,901	27,341
Other Operating Expenses	118.64	753.04	798.43	1,645	1,378	1,491
Operating Expenses	210,783	198,137	105,100	43,222	45,590	65,958
Operating Income	25,300	24,503	9,629	-15,571	-53,917	-69,692
Interest Expense	-824.01	-848.56	-981.48	-1,697	-1,812	-1,629
Interest & Investment Income	229.03	196.52	106.01	156.57	174.95	255.05
Earnings From Equity Investments	4.21	517.9	12,138	-	-	-
Currency Exchange Gain (Loss)	-76.21	-189.08	153.51	1,122	536.76	197.44
Other Non Operating Income (Expenses)	-3,647	-1,735	-477.89	-1,379	174.26	3,811
EBT Excluding Unusual Items	20,986	22,446	20,567	-17,370	-54,843	-67,058
Gain (Loss) on Sale of Assets	-108.89	-108.89	-9.8	9.05	-21.82	-78.66
Asset Writedown	21,613	21,613	-	-577.4	-37,532	-38,377
Other Unusual Items	404.09	-	-	3,483	-	-
Pretax Income	42,894	43,950	20,557	-14,455	-92,397	-105,513
Income Tax Expense	-31,144	-33,280	103.1	-133.75	-60.31	5,592
Earnings From Continuing Operations	74,038	77,230	20,454	-14,321	-92,336	-111,106
Minority Interest in Earnings	0.01	1.37	70.83	236.09	380.26	5,965
Net Income	74,038	77,231	20,525	-14,085	-91,956	-105,141
Net Income to Common	74,038	77,231	20,525	-14,085	-91,956	-105,141
Net Income Growth	131.05%	276.29%	-	-	-	-
Shares Outstanding (Basic)	52	52	51	38	35	35
Shares Outstanding (Diluted)	52	52	51	38	35	35
Shares Change (YoY)	2.53%	2.05%	31.65%	9.70%	-	-
EPS (Basic)	1419.43	1497.00	406.00	-366.79	-2626.90	-3003.55
EPS (Diluted)	1419.43	1497.00	406.00	-367.94	-2639.52	-3003.55
EPS Growth	125.35%	268.72%	-	-	-	-
Free Cash Flow	30,984	44,035	5,284	-1,542	-15,941	-22,398
Free Cash Flow Per Share	594.01	853.55	104.53	-40.17	-455.40	-639.83
Gross Margin	72.45%	72.14%	76.49%	77.21%	-59.61%	-20.55%
Operating Margin	7.76%	7.94%	6.42%	-43.48%	-385.97%	-383.54%
Profit Margin	22.72%	25.02%	13.68%	-39.33%	-658.27%	-578.62%
Free Cash Flow Margin	9.51%	14.27%	3.52%	-4.31%	-114.12%	-123.26%
EBITDA	39,809	39,575	22,558	-2,398	-38,435	-45,493
EBITDA Margin	12.22%	12.82%	15.04%	-6.70%	-275.14%	-250.36%
D&A For EBITDA	14,510	15,071	12,929	13,174	15,482	24,199
EBIT	25,300	24,503	9,629	-15,571	-53,917	-69,692
EBIT Margin	7.76%	7.94%	6.42%	-43.48%	-	-
Effective Tax Rate	-	-	0.50%	-	-	-
Advertising Expenses	-	156,190	72,198	11,684	533.41	858.39

Updated Jan 24, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.